Randomized Phase III Study of High-Dose Fluorouracil Given As a Weekly 24-Hour Infusion With or Without Leucovorin Versus Bolus Fluorouracil Plus Leucovorin in Advanced Colorectal Cancer: European Organization of Research and Treatment of Cancer Gastrointestinal Group Study 40952 - Concepedia

Concepedia

Publication | Closed Access

Randomized Phase III Study of High-Dose Fluorouracil Given As a Weekly 24-Hour Infusion With or Without Leucovorin Versus Bolus Fluorouracil Plus Leucovorin in Advanced Colorectal Cancer: European Organization of Research and Treatment of Cancer Gastrointestinal Group Study 40952

158

Citations

14

References

2003

Year

C-H Köhne, J. Wils, M. Lorenz, Patrick Schöffski, R. Voigtmann, Carsten Bokemeyer, Manfred P. Lutz, Ulrich R. Kleeberg, Karsten Ridwelski, R. Souchon,

Journal of Clinical Oncology

Abstract

Neither FU24h + LV nor FU24h prolong survival, relative to bolus FU + LV. Leucovorin increases PFS if added to FU24h, but increases toxicity.

References

	Year	Citations
Randomized trial comparing monthly low-dose leucovorin and fluorouracil bolus with bimonthly high-dose leucovorin and fluorouracil bolus plus continuous infusion for advanced colorectal cancer: a French intergroup study. Aimery de Gramont, J.-F. Bosset, C Milan, Journal of Clinical Oncology	1997	904
Mortality Associated With Irinotecan Plus Bolus Fluorouracil/Leucovorin: Summary Findings of an Independent Panel Mace L. Rothenberg, Neal J. Meropol, Elizabeth Poplin, Journal of Clinical Oncology	2001	425
Phase II study of fluorouracil and its modulation in advanced colorectal cancer: a Southwest Oncology Group study. Cynthia G. Leichman, Thomas R. Fleming, Franco M. Muggia, Journal of Clinical Oncology	1995	360
A phase II study of weekly 24-hour infusion with high-dose fluorouracil with leucovorin in colorectal carcinoma. Bach Ardalan, Loresita Antonia Chua, Er Ming Tian, Journal of Clinical Oncology High-dose FluorouracilGastrointestinal OncologyMedicinePharmacologyGastroenterology	1991	199
Effective biomodulation by leucovorin of high-dose infusion fluorouracil given as a weekly 24-hour infusion: results of a randomized trial in patients with advanced colorectal cancer. C.-H. Köhne, Patrick Schöffski, H. Wilke, Journal of Clinical Oncology	1998	153
A randomized phase I and II study of short-term infusion of high-dose fluorouracil with or without N-(phosphonacetyl)-L-aspartic acid in patients with advanced pancreatic and colorectal cancers. Bach Ardalan, Gurtej Singh, Howard Silberman Journal of Clinical Oncology GastroenterologyPharmacotherapyIi StudyMetronomic ChemotherapyWeekly Fluorouracil	1988	132
Phase I Study of a Weekly Schedule of Irinotecan, High-Dose Leucovorin, and Infusional Fluorouracil as First-Line Chemotherapy in Patients With Advanced Colorectal Cancer U. Vanhoefer, A. Harstrick, Claus‐Henning Köhne, Journal of Clinical Oncology	1999	83
Fluorouracil Modulation in Colorectal Cancer: Lack of Improvement With N -Phosphonoacetyl- l -Aspartic Acid or Oral Leucovorin or Interferon, But Enhanced Therapeutic Index With Weekly 24-Hour Infusion Schedule—An Eastern Cooperative Oncology Group/Cancer and Leukemia Group B Study Peter J. O’Dwyer, Judith Manola, Frank H. Valone, Journal of Clinical Oncology	2001	80
Biochemical and pharmacologic basis for potentiation of 5-fluorouracil action by leucovorin. Rustum Ym, Fabio Trave, Zakrzewski Sf, PubMed Pharmaceutical Science5-Fluorouridine TriphosphatePharmacotherapyAdvanced Colorectal CancerPharmaceutical Chemistry	1987	71
Modulation of high-dose infusional fluorouracil by low-dose methotrexate in patients with advanced or metastatic colorectal cancer: final results of a randomized European Organization for Research and Treatment of Cancer Study. G.H. Blijham, T. Wagener, J. Wils, Journal of Clinical Oncology	1996	43

Page 1